It is one of a series of AMPA modulators for the potential treatment of Alzheimer's disease, schizophrenia, and mild cognitive impairment (MCI). An ampakine drug that facilitates activation of glutamatergic AMPA receptors.
References
PubChem Literature
From Data Sources
• Marini, A., et al.: J. Biol. Chem., 273, 29394 (1996)
• Balkowiec, A., et al.: J. Neurosci., 22, 10399 (1996)
• Dicou, E., et al.: Brain Res., 970, 221 (1996)
• Arai, A., et al.: J. Pharmacol. Exp. Ther., 278, 627 (1996)